Related Experiment Videos

The contribution of six polymorphisms to cardiovascular risk in a Dutch high-risk primary care population: the

A W Plat1, H E J H Stoffers, O H Klungel

  • 1Department of General Practice, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Center, Maastricht, The Netherlands.

Journal of Human Hypertension
|February 27, 2009
PubMed

Insights

Genetic variations in six key genes showed a protective effect against cardiovascular disease (CVD) in a Dutch population. However, these genetic markers offered minimal improvement in predicting CVD risk alongside traditional factors.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Epidemiology

Background:

  • Cardiovascular disease (CVD) poses a significant health burden, particularly in populations with prevalent risk factors.
  • Understanding the genetic underpinnings of CVD is crucial for improving risk prediction and prevention strategies.

Purpose of the Study:

  • To investigate the association between six specific gene polymorphisms and the occurrence of CVD in a Dutch primary care setting.
  • To evaluate the predictive value of these polymorphisms for CVD risk.

Main Methods:

  • A cross-sectional case-control study involving 232 CVD patients and 571 controls.
  • Genotyping was performed for AGTR1, AGT, ACE, NOS3, GNB3, and ADD1 polymorphisms.
  • Univariate, multivariate, and Receiver Operating Characteristic (ROC) analyses were employed.

Main Results:

  • No significant differences in genotype or allele frequencies were observed between CVD cases and controls.
  • The T-allele of AGT and ADD1 demonstrated a significant protective association with CVD (OR=0.55 and OR=0.52, respectively).
  • Adding the six polymorphisms to traditional risk factors provided only a marginal improvement in CVD risk prediction via ROC analysis.

Conclusions:

  • While AGT and ADD1 polymorphisms show a protective effect, their overall contribution to cardiovascular risk prediction in this primary care population is limited.
  • These specific genetic polymorphisms are unlikely to be major determinants of CVD risk in the Dutch primary care setting studied.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...